

Cleansing Notice under Section 708A(5)(e) of the Corporations Act

Melbourne (Australia), Greer (South Carolina, US) – 9 December 2020: Alexium International Group Limited (ASX: AJX) advises that it has issued 3,856,525 ordinary shares as per the Appendix 2A lodged on 22 December 2020.

The Company advises that the Corporations Act 2001 (Cth) (Corporations Act) restricts the on-sale of securities issued without disclosure unless the sale is exempt under section 708 or section 708A.

This notice is given by the Company under section 708A(5)(e) of the Corporations Act in relation to an issue of shares by the Company without disclosure to investors under Part 6D.2 of the Corporations Act.

As at the date of this notice, the Company has complied with:

- (a) the provisions in Chapter 2M of the Corporations Act as they apply to the Company; and
- (b) Section 674 of the Corporations Act.

The Company confirms that, as at the date of this notice, there is no information that:

- (a) has been excluded from a continuous disclosure notice given to the ASX in accordance with the ASX Listing Rules; and
- (b) investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
 - (i) the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
 - (ii) the rights and liabilities attaching to fully paid ordinary shares.

Bv Order of the Board



Company Secretary

About Alexium International Group Limited

Alexium International Group Limited (ASX: AJX) is a performance chemicals provider for advanced materials applications with a focus on flame retardancy and thermal management. The Company is driven by an innovation model for addressing market gaps with patent-protected technologies. These environmentally friendly solutions have applications for several industries and can be customized to meet customer needs. Key markets for Alexium are military uniforms, workwear, and bedding products. Alexium brands include Alexicool® and Alexiflam®. For additional information about Alexium, please visit www.alexiuminternational.com.

Authorised for release by the Board of Alexium International Group Limited.